Sekisui Diagnostics, LLC announces today the launch of the Silaris RSV Test, the newest assay on their molecular, point-of-care (POC) system.  Silaris is an affordable, CLIA Waived, polymerase chain reaction (PCR) testing platform specifically designed for fast POC diagnosis.

Respiratory Syncytial Virus test (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. While most individuals easily recover without medical intervention, it can lead to serious health problems in infants and older adults.  In 2017 the World Health Organization (WHO) estimated that RSV causes around 33 million serious respiratory infections a year. This results in more than 3 million hospitalizations and nearly 60,000 deaths in children under 5 years of age every year. Nearly half of these hospitalizations and deaths are in children under 6 months of age. Diagnosis of RSV is difficult because the initial symptoms can be similar to those caused by other infectious agents. Considering the RSV virus is highly contagious, accurate diagnosis and prompt treatment of patients can have a positive effect on public health.

“The launch of the Silaris RSV Test is significant as it complements our Silaris Influenza A&B Test and expands the options available on the system so physicians can accurately diagnose respiratory infections while the patient is in the office”, said Robert Schruender, President & CEO of Sekisui Diagnostics.   “This makes the Silaris system an even more versatile tool for physicians, which is critical, especially during the height of the upper respiratory infection season.  We will also continue our efforts to expand the Silaris offering and add more assays in the future.”

Silaris is an affordable, CLIA-waived PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC).  The Silaris system helps physicians diagnose with the convenience and procedural familiarity of traditional rapid immunoassay tests.  Both the Silaris Flu A/Flu B and RSV tests are indicated for use with nasal swab collection that is less invasive than nasopharyngeal swabs and allows for a more comfortable specimen collection experience for the patient.

For more information visit us at www.silaris.com